Researchers at Memorial Sloan-Kettering Cancer Center and Eureka Therapeutics have shown the anti-cancer efficacy of ESKM in resistant human Ph+ ALL.

ESKM is a human IgG1 T-cell receptor mimic monoclonal antibody directed to a 9 amino acid sequence of WT1 in the context of cell surface HLA-A*02. The antibody is therapeutically effective, alone and in combination with tyrosine kinase inhibitors (TKIs,) against Philadelphia chromosome positive acute leukemia in murine models, including a leukemia with the most common, pan-TKI, gate keeper resistance mutation, T315I. In combination with tyrosine kinase inhibitors, ESKM can result in cure of Ph+ ALL in murine models.

The antibody was developed under a collaborative effort between Eureka Therapeutics and Memorial Sloan-Kettering Cancer Center.

Read the article

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text.